| Project/Area Number |
21890318
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | National Institute of Biomedical Innovation |
|---|
Principal Investigator |
NAGANO Kazuya National Institute of Biomedical Innovation, 創薬基盤研究部バイオ創薬プロジェクト, 研究員 (40548301)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥2,652,000 (Direct Cost: ¥2,040,000、Indirect Cost: ¥612,000)
Fiscal Year 2010: ¥1,261,000 (Direct Cost: ¥970,000、Indirect Cost: ¥291,000)
Fiscal Year 2009: ¥1,391,000 (Direct Cost: ¥1,070,000、Indirect Cost: ¥321,000)
|
|---|
| Keywords | メタボリックシンドローム / Non-alcoholic steatohepatitis(NASH) / Non-alcoholic fatty liver disease(NAFLD) / バイオマーカー / NAFLD / NASH / 抗体プロテオミクス技術 |
|---|
| Research Abstract |
It has been estimated that non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), early stage of NASH, become main factors to cause liver cancer and hepatic cirrhosis in future. Therefore, development of diagnostic and therapeutic techniques is urgently needed. However these diseases are hardly known, due to having been recently recognized. In this study, we searched for NAFLD-related proteins and resulted in successfully identifying 8 kinds of candidate proteins more highly expressed in liver of NAFALD model mice.
|
